Strengthening Post-market Surveillance and Risk Management of Medical Devices in Canada

Strengthening Post-market Surveillance and Risk Management of Medical Devices in Canada

Published on August 20, 2018

Author: Bhavesh Patel, C. Chem.

Health Canada recently informed stakeholders, in particular manufacturers and importers of medical devices, of its intent to propose regulatory changes to strengthen post-market surveillance and risk management of medical devices in Canada. The proposed regulatory reforms will involve amendments to the Medical Devices Regulations.

Health Canada has cited several reasons for the proposed changes:

-  an increase in the complexity of medical devices;

-  an increase in the generation and use of real-world data and evidence amongst international regulators;

- a push for greater alignment of regulations with those of other countries; and

- a need for an environment that supports the integration of new technologies into the health care system while maintaining patient safety.

To review the proposed changes in full, please follow the link in the reference section below. 

Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.

Reference:

https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/medical-devices/noi-strengthening-post-market-surveillance-risk-management-medical-devices.htm

Related Articles

Value-Based Drug Pricing in Canada and its Limitations

Value-Based Drug Pricing in Canada and its Limitations

Drug pricing is a complex and controversial issue that often sparks debates among patients, pharmaceutical companies, and the government. Prices can vary significantly...

Addressing Underrepresentation in Clinical Trials: FDA's Diversity Action Plan

Addressing Underrepresentation in Clinical Trials: FDA's Diversity Action Plan

The U.S. Food and Drug Administration (FDA) released a new draft guidance in June 2024 to enhance the diversity of clinical trial participants. The guidance details the...

VIRTUAL HEALTHCARE IN CANADA

VIRTUAL HEALTHCARE IN CANADA

“Virtual care” is defined as any “interaction between patients and/or members of their circle of care, occurring remotely, using any forms of communication or...